SCHEMBL9940772

SCHEMBL9940772

CC1(C)OC2[C@H](n3cnc4c(N)ncnc43)O[C@H](CN)[C@H]2O1

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PI4KA P42356 2/20 0.82
PI4K2B Q8TCG2 2/20 0.82
PI4K2A Q9BTU6 2/20 0.82
PI4KB Q9UBF8 2/20 0.82
RXFP1 Q9HBX9 1/20 0.70
P2RX1 P51575 1/20 0.64
P2RX3 P56373 1/20 0.64
P2RX4 Q99571 1/20 0.64
AMD1 P17707 3/20 0.62
ADORA3 P0DMS8 3/20 0.54
DPP4 P27487 1/20 0.54
MEN1 O00255 1/20 0.54
SLC28A1 O00337 1/20 0.54
MAP3K7 O43318 1/20 0.54
SLC28A2 O43868 1/20 0.54
GAPDH P04406 1/20 0.54
MAPK1 P28482 1/20 0.54
ADORA2A P29274 1/20 0.54
ADORA2B P29275 1/20 0.54
ADORA1 P30542 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19711603 1.00 PI4KA (0.82) PI4KAPI4K2BPI4K2API4KBRXFP1
SCHEMBL20152361 1.00 PI4KA (0.82) PI4KAPI4K2BPI4K2API4KBRXFP1
SCHEMBL16128949 1.00 PI4KA (0.82) PI4KAPI4K2BPI4K2API4KBRXFP1
SCHEMBL12899828 1.00 PI4KA (0.82) PI4KAPI4K2BPI4K2API4KBRXFP1
SCHEMBL460252 1.00 PI4KA (0.82) PI4KAPI4K2BPI4K2API4KBRXFP1
SCHEMBL16128942 1.00 PI4KA (0.82) PI4KAPI4K2BPI4K2API4KBRXFP1
SCHEMBL12928304 1.00 PI4KA (0.82) PI4KAPI4K2BPI4K2API4KBRXFP1
SCHEMBL460251 1.00 PI4KA (0.82) PI4KAPI4K2BPI4K2API4KBRXFP1
SCHEMBL20155850 1.00 PI4KA (0.82) PI4KAPI4K2BPI4K2API4KBRXFP1
SCHEMBL29407102 1.00 PI4KA (0.82) PI4KAPI4K2BPI4K2API4KBRXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230287033-A1 METHODS OF SYNTHESIZING SUBSTITUTED PURINE COMPOUNDS Epizyme, Inc. 2023-09-14 US disclosed
US-11753433-B2 Methods of synthesizing substituted purine compounds Epizyme, Inc. (US) 2023-09-12 US disclosed
US-20180134744-A1 METHODS OF SYNTHESIZING SUBSTITUTED PURINE COMPOUNDS Epizyme, Inc. 2018-05-17 US disclosed
US-20180134745-A1 METHODS OF SYNTHESIZING SUBSTITUTED PURINE COMPOUNDS Epizyme, Inc. 2018-05-17 US disclosed
US-9738679-B2 Methods of synthesizing substituted purine compounds Epizyme, Inc. (US) 2017-08-22 US disclosed
US-20160068559-A1 Modulators of Histone Methyltransferase, and Methods of Use Thereof Epizyme, Inc. 2016-03-10 US disclosed
US-20160024134-A1 METHODS OF SYNTHESIZING SUBSTITUTED PURINE COMPOUNDS Epizyme, Inc. 2016-01-28 US disclosed
US-9175032-B2 Methods of synthesizing substituted purine compounds Epizyme, Inc. (US) 2015-11-03 US disclosed
US-9029343-B2 Modulators of histone methyltransferase, and methods of use thereof Epizyme, Inc. (US) 2015-05-12 US disclosed
US-20150011495-A1 Methods of Synthesizing Substituted Purine Compounds Epizyme, Inc. (US) 2015-01-08 US disclosed
US-20130310333-A1 Modulators of Histone Methyltransferase, and Methods of Use Thereof Epizyme, Inc. (US) 2013-11-21 US disclosed
EP-2646455-A2 MODULATORS OF HISTONE METHYLTRANSFERASE, AND METHODS OF USE THEREOF Epizyme, Inc. (US) 2013-10-09 EP disclosed
WO-2012082436-A2 MODULATORS OF HISTONE METHYLTRANSFERASE, AND METHODS OF USE THEREOF Epizyme, Inc. (US) 2012-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150011495-A1 Methods of Synthesizing Substituted Purine Compounds DOT1L, MECP2, TDP1 PI4KA 3857/4885PI4K2B 3873/4885PI4K2A 3832/4885
US-20160024134-A1 METHODS OF SYNTHESIZING SUBSTITUTED PURINE COMPOUNDS DOT1L, MECP2, TDP1 PI4KA 3857/4885PI4K2B 3873/4885PI4K2A 3832/4885
US-20180134744-A1 METHODS OF SYNTHESIZING SUBSTITUTED PURINE COMPOUNDS DOT1L, MECP2, TDP1 PI4KA 3857/4885PI4K2B 3873/4885PI4K2A 3832/4885
US-20160068559-A1 Modulators of Histone Methyltransferase, and Methods of Use Thereof EHMT1, EHMT2, HNMT PI4KA 1844/4885PI4K2B 1901/4885PI4K2A 1942/4885
US-20130310333-A1 Modulators of Histone Methyltransferase, and Methods of Use Thereof EHMT1, EHMT2, HNMT PI4KA 1844/4885PI4K2B 1901/4885PI4K2A 1942/4885
US-11753433-B2 Methods of synthesizing substituted purine compounds DOT1L, MECP2, TDP1 PI4KA 3857/4885PI4K2B 3873/4885PI4K2A 3832/4885
US-20180134745-A1 METHODS OF SYNTHESIZING SUBSTITUTED PURINE COMPOUNDS DOT1L, MECP2, TDP1 PI4KA 3857/4885PI4K2B 3873/4885PI4K2A 3832/4885
US-20230287033-A1 METHODS OF SYNTHESIZING SUBSTITUTED PURINE COMPOUNDS DOT1L, MECP2, TDP1 PI4KA 3857/4885PI4K2B 3873/4885PI4K2A 3832/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.